ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Vir Biotechnology, Inc. ?
1
With a growth in Net Sales of 26595.83%, the company declared Outstanding results in Sep 25
- The company has declared positive results in Jan 70 after 4 consecutive negative quarters
- OPERATING CASH FLOW(Y) Highest at USD -453.55 MM
- NET PROFIT(HY) Higher at USD -261.68 MM
2
Rising Promoter Confidence
- Promoters have increased their stake in the company by 3.35% over the previous quarter and currently hold 27.03% of the company
- Promoters increasing their stake is a sign of high confidence in the future of the business
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Vir Biotechnology, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Vir Biotechnology, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Vir Biotechnology, Inc.
24.86%
-0.32
72.75%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-25.93%
EBIT Growth (5y)
-168.03%
EBIT to Interest (avg)
1.09
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.84
Sales to Capital Employed (avg)
0.07
Tax Ratio
0.24%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
93.83%
ROCE (avg)
17.07%
ROE (avg)
12.10%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.94
EV to EBIT
-2.01
EV to EBITDA
-2.06
EV to Capital Employed
3.53
EV to Sales
62.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-175.34%
ROE (Latest)
-59.52%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -453.55 MM
NET PROFIT(HY)
Higher at USD -261.68 MM
-15What is not working for the Company
NET SALES(HY)
At USD 1.45 MM has Grown at -73.35%
ROCE(HY)
Lowest at -49.06%
RAW MATERIAL COST(Y)
Grown by 4,523% (YoY
CASH AND EQV(HY)
Lowest at USD 1,202.96 MM
DEBT-EQUITY RATIO
(HY)
Highest at -51.32 %
PRE-TAX PROFIT(Q)
At USD -163.75 MM has Fallen at -28.63%
NET PROFIT(Q)
At USD -163.92 MM has Fallen at -28.69%
Here's what is working for Vir Biotechnology, Inc.
Operating Cash Flow
Highest at USD -453.55 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Depreciation
Highest at USD 3 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Vir Biotechnology, Inc.
Net Sales
At USD 1.45 MM has Grown at -73.35%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -163.75 MM has Fallen at -28.63%
over average net sales of the previous four periods of USD -127.3 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -163.92 MM has Fallen at -28.69%
over average net sales of the previous four periods of USD -127.37 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 1,202.96 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -51.32 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 4,523% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
